Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.4.1979

Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats  

Abdel-Hamid, Nabil Mohie (Biochemistry Department, Faculty of Pharmacy, Kafr-El-Sheikh University)
Wahid, Ahmed (Biochemistry Department, Faculty of Pharmacy, Minia University)
Nazmy, Maiiada Hassan (Biochemistry Department, Faculty of Pharmacy, Minia University)
Eisa, Marwa Abdel-Moniem (Biochemistry Department, Faculty of Pharmacy, Minia University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.4, 2016 , pp. 1979-1985 More about this Journal
Abstract
Background: Complementary and alternative medicine has been highly appreciated as a supportive regimen for classical treatment strategies. Here we offer a nutrition-based adjuvant therapy for liver fibrosis, a major risk factor for cirrhosis and hepatocellular carcinoma. Aim of the study: To evaluate the possible hepatoprotective effects of Jerusalem artichoke tubers (JAT) in combination with interferon and ribavirin. Materials and Methods: Twelve groups of rats were administered JAT, interferon and ribavirin either separately or in combination from day one of $CCL_4$ administration until the end of the study. Animals were killed after 8 weeks of $CCL_4$-induced hepatotoxicity. Results: Hepatocytes from rats treated with triple combination of interferon, ribavirin, and JAT showed more less normal architecture compared to $CCL_4$-treated rats. We also detected significantly higher hepatic protein expression levels of p53, BAX and transforming growth factor-${\beta}$ (TGF-${\beta}$) in the $CCL_4$-intoxicated group compared to normal controls, as evidenced by immunohistochemical staining and western blotting analyses. Addition of JAT as a supportive regimen improved response to ribavirin and interferon and effectively participated in retaining normal histopathological and biochemical criteria and significantly lowered protein expression of p53, BAX, and TGF-${\beta}$. Conclusions: We suggest that addition of JAT as a supportive r egimen to interferon and ribavirin effectively potentiates their anti-fibrotic effects.
Keywords
Jerusalem artichoke tubers; rat liver model; fibrosis; p53; BAX; TGF-${\beta}$;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Abdel Salam OM, Sleem AA, Omara EA, et al (2007). Effect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats. Drug Target Insights, 2, 19-27.
2 Abdel-Hamid NM, Nazmy MH, Mahmoud AW, et al (2011). A survey on herbal management of hepatocellular carcinoma. World J Hepatol, 3, 175-83.   DOI
3 Abdel-Hamid NM, Nazmy MH, Wahid A, et al (2015). Jerusalem artichoke attenuates experimental hepatic fibrosis via modulation of apoptotic signaling and fibrogenic activity. Biochemistry Biotechnol Res, 3, 43-50.
4 Aithal GP, Watkins PB, Andrade RJ, et al (2011). Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 89, 806-15.   DOI
5 Akyol G, Dursun A, Poyraz A, et al (1999). P53 and proliferating cell nuclear antigen (PCNA) expression in non-tumoral liver diseases. Pathol Int, 49, 214-21.   DOI
6 Althnaian T, Albokhadaim I, El-Bahr SM (2013). Biochemical and histopathological study in rats intoxicated with carbontetrachloride and treated with camel milk. Springerplus, 2, 57.   DOI
7 Arici OF, Cetin N (2011). Protective role of ghrelin against carbon tetrachloride (CCl(4))-induced coagulation disturbances in rats. Regul Pept, 166, 139-42.   DOI
8 Aslan M, Orhan N, Orhan DD, et al (2010). Hypoglycemic activity and antioxidant potential of some medicinal plants traditionally used in Turkey for diabetes. J Ethnopharmacol, 128, 384-9.   DOI
9 Attallah AM, Shiha GE, Ismail H, et al (2009). Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem, 42, 455-61.   DOI
10 Baldo V, Baldovin T, Trivello R, et al (2008). Epidemiology of HCV infection. Curr Pharm Des, 14, 1646-54.   DOI
11 Bataller R, Brenner DA (2005). Liver fibrosis. J Clin Invest, 115, 209-18.   DOI
12 Castilla A, Prieto J, Fausto N (1991). Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med, 324, 933-40.   DOI
13 Blight KJ, McKeating JA, Marcotrigiano J, et al (2003). Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol, 77, 3181-90.   DOI
14 Boigk G, Stroedter L, Herbst H, et al (1997). Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatol, 26, 643-9.   DOI
15 Brattin WJ, Glende EA, Jr., Recknagel RO (1985). Pathological mechanisms in carbon tetrachloride hepatotoxicity. J Free Radic Biol Med, 1, 27-38.   DOI
16 Chang WC, Jia H, Aw W, et al (2014). Beneficial effects of soluble dietary Jerusalem artichoke (Helianthus tuberosus) in the prevention of the onset of type 2 diabetes and nonalcoholic fatty liver disease in high-fructose diet-fed rats. Br J Nutr, 112, 709-17.   DOI
17 Chang XM, Chang Y, Jia A (2005). Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis. World J Gastroenterol, 11, 2634-6.   DOI
18 CR T (1994). The current role of immunohistochemistry in diagnostic pathology. Adv Pathol Lab Med, 7.
19 Domitrovic R, Jakovac H, Tomac J, et al (2009). Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol Appl Pharmacol, 241, 311-21.   DOI
20 EA Z (2009). Physiological response to diets fortified with Jerusalem artichoke tubers (Helianthus tuberosus L.) powder by diabetic rats. American-Eurasian J Agric Environ Sci, 5, 682-8.
21 Green DR (2000). Apoptotic pathways: paper wraps stone blunts scissors. Cell, 102, 1-4.   DOI
22 Fujii H, Nishimura T, Umemura A, et al (2015). Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol, 7, 2841-8.   DOI
23 Gao B, Bataller R (2011). Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterol, 141, 1572-85.   DOI
24 Gebhardt R (2002). Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med, 68, 289-96.   DOI
25 Guo XL, Liang B, Wang XW, et al (2013). Glycyrrhizic acid attenuates CCl(4)-induced hepatocyte apoptosis in rats via a p53-mediated pathway. World J Gastroenterol, 19, 3781-91.   DOI
26 Helm M, Brule H, Giege R, et al (1999). More mistakes by T7 RNA polymerase at the 5 ' ends of in vitro-transcribed RNAs. RNA, 5, 618-21.   DOI
27 Hengartner MO (2000). The biochemistry of apoptosis. Nature, 407, 770-6.   DOI
28 Kucukgergin C, Aydin AF, Ozdemirler-Erata G, et al (2010). Effect of artichoke leaf extract on hepatic and cardiac oxidative stress in rats fed on high cholesterol diet. Biol Trace Elem Res, 135, 264-74.   DOI
29 Lotersztajn S, Julien B, Teixeira-Clerc F, et al (2005). Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol, 45, 605-28.   DOI
30 Mayo MJ (2011). Management of autoimmune hepatitis. Curr Opin Gastroenterol, 27, 224-30.   DOI
31 McCay PB, Lai EK, Poyer JL, et al (1984). Oxygen- and carboncentered free radical formation during carbon tetrachloride metabolism. Observation of lipid radicals in vivo and in vitro. J Biol Chem, 259, 2135-43.
32 Nobili V, Carter-Kent C, Feldstein AE (2011). The role of lifestyle changes in the management of chronic liver disease. BMC Med, 9, 70.   DOI
33 Mehmetcik G, Ozdemirler G, Kocak-Toker N, et al (2008). Role of carnosine in preventing thioacetamide-induced liver injury in the rat. Peptides, 29, 425-9.   DOI
34 Minano C, Garcia-Tsao G (2010). Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am, 39, 681-95.   DOI
35 Muriel P (1996). Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in the rat. J Hepatol, 24, 614-21.   DOI
36 Panasiuk A, Dzieciol J, Panasiuk B, et al (2006). Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol, 12, 6198-202.   DOI
37 Papakyriakou P, Tzardi M, Valatas V, et al (2002). Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis, 7, 133-41.   DOI
38 Punzi R, Paradiso A, Fasciano C, et al (2014). Phenols and antioxidant activity in vitro and in vivo of aqueous extracts obtained by ultrasound-assisted extraction from artichoke by-products. Nat Prod Commun, 9, 1315-8.
39 Ramalho RM, Cortez-Pinto H, Castro RE, et al (2006). Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol, 18, 21-9.   DOI
40 Reitman S, Frankel S (1957). A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol, 28, 56-63.   DOI
41 Riley TR, 3rd, Bhatti AM (2001). Preventive strategies in chronic liver disease: part II. Cirrhosis. Am Fam Physician, 64, 1735-40.
42 Roderfeld M, Weiskirchen R, Wagner S, et al (2006b). Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J, 20, 444-54.   DOI
43 Roberfroid MB, Delzenne NM (1998). Dietary fructans. Annu Rev Nutr, 18, 117-43.   DOI
44 Roberfroid MB, Van Loo JA, Gibson GR (1998). The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr, 128, 11-9.   DOI
45 Roderfeld M, Geier A, Dietrich CG, et al (2006a). Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver Int, 26, 579-86.   DOI
46 Sakaida I, Tsuchiya M, Kawaguchi K, et al (2003). Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol, 38, 762-9.
47 Schafer T, Scheuer C, Roemer K, et al (2003). Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. FASEB J, 17, 660-7.   DOI
48 Schuppan D, Afdhal NH (2008). Liver cirrhosis. Lancet, 371, 838-51.   DOI
49 Schuppan D, Jia JD, Brinkhaus B, et al (1999). Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology, 30, 1099-104.
50 Serni E, Audino V, Del Carlo S, et al (2013). Determination of water-soluble vitamins in multivitamin dietary supplements and in artichokes by micellar electrokinetic chromatography. Nat Prod Res, 27, 2212-5.   DOI
51 Shahnazari P, Sayehmiri K, Minuchehr Z, et al (2014). The increased level of serum p53 in hepatitis b-associated liver cirrhosis. Iran J Med Sci, 39, 446-51.
52 Towbin H, Staehelin T, Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A, 76, 4350-4.   DOI
53 Solbrig MV, Schlaberg R, Briese T, et al (2002). Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats. Antimicrob Agents Chemother, 46, 2287-91.   DOI
54 Tasci I, Mas MR, Vural SA, et al (2007). Pegylated interferonalpha plus taurine in treatment of rat liver fibrosis. World J Gastroenterol, 13, 3237-44.   DOI
55 Thursz M, Yee L, Khakoo S (2011). Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis, 31, 115-27.   DOI
56 Tsamandas AC, Thomopoulos K, Zolota V, et al (2003). Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Mod Pathol, 16, 1273-88.   DOI
57 Tsushima H, Kawata S, Tamura S, et al (1999). Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol, 30, 1-7.
58 Veillon P, Fouchard-Hubert I, Larrey D, et al (2015). Does epoetin beta still have a place in peginterferon alpha-2a plus ribavirin treatment strategies for chronic hepatitis c? J Interferon Cytokine Res.
59 Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature, 408, 307-10.   DOI
60 Vousden KH, Lu X (2002). Live or let die: the cell’s response to p53. Nat Rev Cancer, 2, 594-604.   DOI
61 Watson D, Rogers JA (1961). A study of six representative methods of plasma bilirubin analysis. J Clin Pathol, 14, 271-8.   DOI
62 Zawistowski J, Blank G, Murray ED (1986). Polyphenol oxidase activity in Jerusalem artichokes (Helianthus tuberosus L.). Can Institute Food Science Technol J, 19, 210-4.   DOI
63 Xu XB, Leng XS, Yang X, et al (2004). Obstruction of TGF-beta1 signal transduction can decrease the process of hepatocellular carcinoma in mice induced by CCl4/ethanol. Zhonghua Yi Xue Za Zhi, 84, 1122-5 (in Chinese).